Grzegorz L. Chadzynski1, 2, Sotirios Bisdas3, Gisela E. Hagberg1, 2, Rolf Pohmann2, Gunamony Shajan2, Rupert Kolb3, Uwe Klose3, Klaus Scheffler1, 2
1Dept. Biomedical Magnetic Resonance, University Hospital Tuebingen, Tuebingen, Germany; 2Dept. High-Field Magnetic Resonance, Max Planc Institute for Biological Cybernetics, Tuebingen, Germany; 3Dept. Neuroradiology, University Hospital Tuebingen, Tuebingen, Germany
Recent studies have shown that in-vivo 1H CSI at ultra-high magnetic field may benefit from the gain in signal to noise ratio and spectral resolution. This could be of interest when assessing the physiopathology of brain tumors, where detection of 2-hydroxyglutarate (2HG) with 1H CSI at a field strength of 3 T has recently been reported. This particular compound is associated with mutations in isocitrate dehydrogenasis (IDH) frequently occurring in gliomas. The aim of this study was to verify whether proton CSI at a field strength of 9.4 T can facilitate the diagnosis of human brain tumors.